Belén Valenzuela

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 10

Top Topics

Multiple Sclerosis

Monoclonal Antibody

Top Venues

Clinical pharmacology and therapeutics

Clinical pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics 113 (3) (2023)
Terra M Kruger, Belén Valenzuela, Charles D Thompson, Sivi Ouwerkerk-Mahadevan, Juan Jose Perez Ruixo
Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis. Clinical pharmacokinetics (2023)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics 113 (3) (2023)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics 113 (3) (2023)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics 113 (3) (2023)
Anna Dari, Muriel Boulton, Martine Neyens, Mathieu Le Gars, Belén Valenzuela, Georgi Shukarev, Vicky Cárdenas, Javier Ruiz-Guiñazú, Jerald Sadoff, Richard M W Hoetelmans, Juan José Pérez Ruixo
Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach. Clinical pharmacology and therapeutics (2022)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics (2022)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan José Pérez-Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Effect of Ponesimod on Heart Rate in Patients with Multiple Sclerosis. Clinical pharmacology and therapeutics (2022)
Per Olsson Gisleskog, Belén Valenzuela, Tatiana Scherz, Michel Burcklen, Juan Jose Perez Ruixo, Italo Poggesi
An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis. Clinical pharmacokinetics 60 (9) (2021)
Belén Valenzuela, Juan Jose Perez Ruixo, Quentin Leirens, Sivi Ouwerkerk-Mahadevan, Italo Poggesi
Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis. Clinical pharmacokinetics 60 (9) (2021)